Literature DB >> 17932750

Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers.

Takao Ohtsuka1, Yuji Nakafusa, Seiji Sato, Yoshihiko Kitajima, Masayuki Tanaka, Kohji Miyazaki.   

Abstract

We previously demonstrated that false-positive findings for tumor markers are frequently observed, and that the sensitivity of marker monitoring for early detection of the recurrence is low after curative resection of gastric cancer. The aim of this study was to investigate whether such characters are specific to gastric cancer. Serum carcinoembryonic antigen and/or carbohydrate antigen 19-9 were periodically assessed in 258 patients who underwent curative gastrectomy for gastric cancer (n = 161) or curative resection for colorectal cancer (n = 97). The frequency of false-positive findings for the tumor markers, the sensitivity of the marker monitoring for detection of the recurrence, and the characteristics of such cases were compared between these two cancer groups. During the median follow-up period of 30 months, recurrence developed in 14% of gastric cancer and 23% of colorectal cancer patients. A false positive with the tumor marker was frequently observed in patients after gastrectomy compared with after colorectal surgery. The sensitivity of the marker monitoring regarding early detection of recurrence was higher in patients with colorectal cancer than those with gastric cancer, especially in cases of advanced stage. As a result, the accuracy of marker monitoring for the detection of recurrence was higher in patients after the resection of colorectal cancer than that of gastric cancer. Surgeons and oncologists should thus be aware that the role of the tumor marker monitoring after a curative operation differs between patients with gastric and colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17932750     DOI: 10.1007/s10620-007-0046-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.

Authors:  F Nomura; A Koyama; M Ishijima; S Takano; M Narita; T Nakai
Journal:  Oncol Rep       Date:  1998 Mar-Apr       Impact factor: 3.906

2.  A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan.

Authors:  Seigo Kitano; Norio Shiraishi; Ichiro Uyama; Kenichi Sugihara; Nobuhiko Tanigawa
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

3.  Hyperglycemia after gastrectomy as a prediabetic state. Clinical study of 100 postgastrectomy patients.

Authors:  T Tobe; M Kouchi; H Tanimura; C H Huang
Journal:  Arch Surg       Date:  1967-06

4.  Serum CEA levels facilitate detection of recurrences of cancer in patients after gastrectomy.

Authors:  R Tamada; Y Hiramoto; S Tsujitani; T Nozuka; T Okamura; H Masuda; K Sugimachi; K Inokuchi
Journal:  Jpn J Surg       Date:  1985-01

Review 5.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

6.  Clinical outcomes of EMR for gastric tumors: historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection.

Authors:  Kenichiro Watanabe; Shinichi Ogata; Seiji Kawazoe; Kazuyo Watanabe; Takanori Koyama; Tetsuro Kajiwara; Yuichiro Shimoda; Yukari Takase; Kouji Irie; Masanobu Mizuguchi; Seiji Tsunada; Ryuichi Iwakiri; Kazuma Fujimoto
Journal:  Gastrointest Endosc       Date:  2006-05       Impact factor: 9.427

7.  False-positive findings for tumor markers after curative gastrectomy for gastric cancer.

Authors:  Takao Ohtsuka; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Yuji Nakafusa; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2007-05-03       Impact factor: 3.199

8.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

9.  Elevated serum CA19-9 levels in poorly controlled diabetic patients.

Authors:  N Nakamura; O Aoji; T Yoshikawa; K Mori; S Kajiyama; Y Kitagawa; T Kanatsuna; M Kondo
Journal:  Jpn J Med       Date:  1986-08

10.  CA72-4 compared with carcinoembryonic antigen as a tumour marker for gastric cancer.

Authors:  R Hamazoe; M Maeta; T Matsui; S Shibata; S Shiota; N Kaibara
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

View more
  3 in total

Review 1.  MicroRNAs: novel biomarkers for gastrointestinal carcinomas.

Authors:  Li Xie; Xiaoping Qian; Baorui Liu
Journal:  Mol Cell Biochem       Date:  2010-04-27       Impact factor: 3.396

Review 2.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

3.  Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.

Authors:  Wei Wang; Xiao-Long Chen; Shen-Yu Zhao; Yu-Hui Xu; Wei-Han Zhang; Kai Liu; Xin-Zu Chen; Kun Yang; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Oncotarget       Date:  2016-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.